Entyvio Takes Lead As Takeda Pursues Turnaround
Executive Summary
Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.
You may also be interested in...
Takeda Enlists Real World Evidence To Boost Marketed Entyvio
Japan’s Takeda says it has confirmed the benefits of its best-selling inflammatory bowel disease therapy Entyvio in US medical practice through the collection of real world evidence.
Takeda Closing In Again On Valeant Assets?
Takeda and Valeant are rumored to have restarted talks over some form of potential deal, this time reportedly focusing on a possible offer by the Japanese firm for Valeant's gastrointestinal business unit Salix.
New Bridge Venture Aligns With Takeda Externalization Strategy
A new collaborative academic-industry medicines development venture involving Takeda has started operations in the US, aiming to smooth and speed the passage of basic research projects through clinical trials and eventually to the market.